The company aims to scale production of its genetically modified pig organs for human transplantation. Rendering courtesy McCord

Maryland-based United Therapeutics Corp. has opened a new 77,448-square-foot facility to manufacture xeno-organs in Northeast Houston’s growing biotech hub, Generation Park.

The new Houston location is United Therapeutics’ third Designated Pathogen-Free (DPF) site, named for transplant pioneers Dr. Bartley P. Griffith and Dr. Robert A. Montgomery. The company says the new facility will enable it to scale commercial production of its xeno-organs once they receive regulatory approval.

An existing DPF facility in Virginia is supporting clinical trials for the xeno-organs, and a third site in Minnesota will also focus on commercialization with the Houston site, according to the company.

Xeno-organs are organs taken from a non-human animal source and transplanted, implanted or infused into a human recipient.

Currently, United Therapeutics is advancing clinical trials to support a Biologics License Application with the U.S. Food and Drug Administration for its investigational-stage xenotransplantation, UKidney, UThymoKidney and UHeart products. The products all involve working with the genes from humans and pigs.

In 2025, Chron.com reported the company was working to construct an estimated $96 million facility to breed genetically engineered animals. Head of investor relations at United Therapeutics Dewey Steadman told the Houston Business Journal in 2025 that the pigs’ DNA will be edited. In November 2024, a 53-year-old woman in Alabama received a transplanted kidney from UKidney that had 10 gene edits. She had the transplant removed in April 2025, after her body rejected it.

The Dr. Bartley P. Griffith and Dr. Robert A. Montgomery Xenograft Production Facility requires a “strictly controlled, biosecure barrier environment, including air filtration, filtered water, filtered feed supplies, and state-of-the-art decontamination entryways,” according to the company. Being pathogen-free means it includes calibrated air and water conduits to support the transplantability of xenograft products and to prevent contamination. For energy considerations, the building also features solar arrays.

“With our third xenograft production facility now open and clinical trials underway, United Therapeutics is moving closer to its goal of providing transplantable organs to the people who need them,” Martine Rothblatt, chairperson and CEO of United Therapeutics, said in a news release. “It is fitting that this facility is named for Dr. Griffith and Dr. Montgomery, whose first-in-human surgeries turned xenotransplantation from a theoretical possibility into a clinical reality.”

The facility, which wrapped construction in August, is located at 11848 Common Dock Dr. in Generation Park, which will house manufacturing sites for pharmaceutical heavyweights Bristol Myers Squibb and Eli Lilly. Last fall, Eli Lilly tapped Generation Park for its $6.5 billion manufacturing plant, and Bristol Myers Squibb made a $2.3 billion investment in August to bring its state-of-the-art site to the master-planned commercial district.

The TMC's William McKeon and San Jacinto College's Brenda Hellyer signed a memorandum of understanding on April 14. Photo courtesy TMC

New TMC partnership aims to grow Houston’s biomanufacturing workforce

workforce partnership

Houston is a frontrunner in the race to introduce and manufacture advanced therapeutics to the medical world. A new agreement between the Texas Medical Center (TMC) and San Jacinto College (SJC) aims to speed more experts and their technologies towards the finish line.

Earlier this month, the world's largest medical center and the nation’s second-ranked community college announced their new partnership that will set students on a path towards careers not only in life sciences in general, but also in pharmaceutical and biomanufacturing specifically.

SJC already has programs in those majors—its first graduates are now joining the workforce—but working with TMC will help the college recruit new students, as well as aid in enrollment and participation. Thanks to this collaboration, SJC students will benefit from more experiential learning and be able to transition more smoothly into the next steps in their training.

“Houston is a premier global hub for life sciences and biotechnology, and the talent we need to advance therapeutic drugs, diagnostics, and cell and gene therapy is already here,” William McKeon, the TMC’s president and CEO, said in a news release. “With more companies choosing to establish their headquarters in Houston and the daily breakthroughs happening across the TMC campus, partnering with San Jacinto College is an important step toward sustaining that momentum and unlocking even greater innovation and growth through the promising talent that already exists within our state.”

The partnership is currently slated to last two years, but the institutions have the option to extend after that.

For students, their journey to becoming scientists will likely start with Biopath @ TMC, a program that introduces high school students to biomanufacturing careers and what it takes to pursue one. Since its inception two years ago, the program has worked with more than 2,000 students around Harris County.

“This partnership exemplifies San Jacinto College’s ability to design and deliver programs that align with current workforce demands while opening doors for untapped talent across the Houston region,” Brenda Hellyer, SJC chancellor, said in the release. “TMC is a key industry leader in our region, and San Jacinto College has a unique global curriculum that provides the foundation and skills required for students to succeed and graduates to thrive in meaningful careers that will contribute to the innovation and advancement of the life sciences.”

Thanks to this new collaboration, more of Houston’s biomanufacturing workforce will soon be locally grown.

BioWell will now operate Texas BioTechnology’s 33,000-square-foot pilot plant. Photo courtesy First Bight Ventures.

Houston biomanufacturing accelerator adds pilot plant to support scale-ups

new digs

Houston accelerator BioWell announced this month that it has taken over operations of Texas BioTechnology’s pilot plant in Richmond, Texas.

The 33,000-square-foot facility is one of the largest of its kind in the U.S. and features molecular biology labs, advanced automation, fermentation equipment and 16 dedicated benches for early-stage industrial biomanufacturing companies, according to a release from the company. It will allow BioWell to offer on-site education, workforce development, and lab training for students and workers.

BioWell and its founding company, First Bight Ventures, report that the facility should help address the industry's "scale-up bottleneck due to limited pilot- and demonstration-scale infrastructure" in the U.S.

"As a Houston-based accelerator dedicated exclusively to early-stage biomanufacturing startups, partnering with this facility was a natural and highly strategic decision for us. The site is fully operational and offers a strong platform to support biomanufacturing companies, industry leaders, and research institutions, providing critical expertise and infrastructure across a broad range of biotechnology production processes,” Veronica Breckenridge, founder of First Bight Ventures and BioWell, said in a news release.

First Bight Ventures shares that the partnership with the facility will also allow it to better support its portfolio companies and make them more attractive to future investors.

BioWell will host an open house and tours of the fermentation and lab spaces and an overview of current bioindustrial projects Wednesday, May 28, at 10:30 a.m. and 2 p.m. RSVPs are required.

BioWell was originally funded by a $700,000 U.S. Economic Development Administration’s Build to Scale grant and launched as a virtual accelerator for bioindustrial startups. Listen to an interview with Carlos Estrada, head of venture acceleration at BioWell, here.

Houston's San Jacinto College is launching a biotechnology program in early 2024 to be housed in the Center for Biotechnology in Generation Park. Rendering courtesy of McCord

Houston-area college shares more details on new biotechnology program, center

coming soon

Houston's San Jacinto College will roll out a new biotechnology program in early 2024 as it gets closer to its goal of launching the Center for Biotechnology in Generation Park.

In partnership with the Ireland-based National Institute for Bioprocessing Research and Training, the licensed training curriculum will offer regional biopharmaceutical training at the college's South Campus starting in January.

Initially, the 90-hour hybrid training program will provide opportunities for participants to gain experience with "all aspects of biomanufacturing, specialized instrumentation and equipment training, and advanced techniques," according to a statement. Students will earn an onboarding certificate that will help them enter the field.

The college then plans to open the Center for Biotechnology, developed by McCord Development Inc., at its Generation Park Campus in the first quarter of 2025. The state-of-the-art facility is slated to allow for more hands-on training within simulated environments, and will allow students to earn associate of applied science degrees in biomanufacturing technology, as well as credentials for those already in the workforce.

“The biomanufacturing industry is seeing substantial growth in the Greater-Houston area,” Christopher Wild, executive director for the San Jacinto College Center for Biotechnology, says in a statement. “The College’s partnership to offer NIBRT’s premier, industry-leading training right here in the Houston-area represents a firm commitment to bolstering the biomanufacturing workforce pipeline which will help position the region for continued growth.”

The center will also offer programs that are customizable to industry partners' needs, according to a statement, and will provide cost-effective training for new hires. It will be the only NIBRT-licensed training in the Southwest and Southeast region.

“The NIBRT team have been very impressed by San Jacinto’s excellent track record in developing workforce programmes for the Greater Houston Region across a broad range of industrial sectors," Darrin Morrissey, CEO of NIBRT, says in a statement. We are very much looking forward to working with the San Jacinto team to deliver world class biopharma training programs to their students."

The new center is part of Generation Park, a 4,300-acre master-planned development in Northeast Houston. In late 2022, San Jac and McCord, which is developing Generation Park, shared that they had signed a memorandum of understanding with the NIBRT to launch the program and center.

At the time, San Jacinto College was slated to be the institute’s sixth global partner and second U.S. partner.

Over the summer, McCord also revealed plans for its 45-acre biomanufacturing campus at Generation Park.
Generation Park has announced additional biomanufacturing facility development. Rendering courtesy of McCord

Real estate company unveils plans for 45-acre biomanufacturing campus in Northeast Houston

life science upgrade

A Houston-based real estate company has reveals its plans to create a 45-acre biomanufacturing campus in the first phase of a life science development in Generation Park.

McCord Development released its plans for BioHub Two this week. The project will include 500,000 square feet for manufacturing, lab, and office space located in Generation Park, a 4,300-acre master-planned development in Northeast Houston.

The news of the BioHub follows Generation Park's December announcement of the San Jacinto College’s Biotech Training Center, a project in partnership with the National Institute of Biotechnology Research and Training. The institute will have a "bioprocessing pilot plant operated in a realistic GMP simulated and operational manufacturing environment," according to a news release from McCord.

“Houston has consistently been ranked as a burgeoning life science cluster, and BioHub Two has the unique advantage of being a short walk from the region’s only Biotech Training Center at San Jacinto College’s Generation Park campus," says John Flournoy, senior director of sales and leasing.

Last year, the Greater Houston Partnership released data showing the potential for the Bayou City as a hub for biomanufacturing, cell and gene therapy, cancer treatment, drug development, and more. Earlier this summer, Houston maintained its standing as a hub for life sciences on an annual report from CBRE.

“Houston’s high concentration of life sciences employment, healthy funding landscape, access to the Texas’ $6 billion CPRIT grant fund, and commitment to translational research is making it one of the country’s fastest growing life science ecosystems,” says Ryan McCord, president of McCord Development, in the release. “BioHub Two’s location in Generation Park is strategic and cost-effective, as the world-leading research and development facilities at the Texas Medical Center, Houston International Airport and Port of Houston are in close proximity.”

The larger Generation Part plans include two multifamily complexes, a mixed-use development called The Commons, and retail and green spaces.

The Texas Medical Center unveiled its plans for the TMC BioPort, a biomanufacturing and medical supplies distribution engine, almost a year ago. This new campus will span several hundred acres just down the road from TMC and will drive the much-needed repatriation of critical medical supplies and new cell and gene therapies, per a news release.

The opening of the pilot plant marks the debut of Cemvita’s eCO2 business as a wholly owned subsidiary. Photo courtesy of Cemvita

Fast-growing startup with carbon-free solution sets up pilot plant in Houston

big moves

Cleantech startup Cemvita has set up a pilot plant in its hometown of Houston to develop technology for converting carbon emissions as feedstock to make products like fertilizer, plastics, methane, and fuel.

The opening of the pilot plant marks the debut of Cemvita’s eCO2 business as a wholly owned subsidiary. The term eCO2 refers to equivalent carbon dioxide, or a way to measure a combination of greenhouse gases such as carbon dioxide and methane.

With a capacity of more than 14,000 gallons, the plant is producing eCO2 oil, an alternative to soybean oil. The company already is shipping samples of eCO2 products to customers, including renewable-fuel companies and plastics manufacturers.

Cemvita says the biofuel industry is facing feedstock shortages and price fluctuations. Biofuel feedstocks produce starches or sugars that can be converted to produce ethanol, while others produce oil that can be used in biodiesel production, according to the Sustainable Agriculture Research & Education (SARE) program.

“Traditional biofuels, including renewable diesel and sustainable aviation fuel, have relied on oils derived from crops, such as soybean and corn, as well as recycled vegetable oils,” Cemvita says. “As demand grows for petroleum-free alternatives, feedstock is in short supply and must compete with food markets. Crops of soybeans, sugar, and corn use huge swaths of land, and the raw materials require extensive refining — two factors that impede the processes from being sustainable.”

By contrast, eCO2 plants like Cemvita’s can supply feedstock production with minimal land and electricity requirements, and without relying on hydrogen or sunlight, the company says. Furthermore, the output of eCO2 plants is designed to carbon-negative, not just carbon-neutral.

Cemvita’s eCO2 biomanufacturing platform uses engineered microbes that absorb and convert carbon dioxide into feedstocks and finished products.

“The energy transition requires completely new, cost-effective approaches for heavy industry,” Charlie Nelson, chief operating officer of Cemvita, says in a news release. “We built this next-generation pilot plant in response to strong demand from … partners who are actively seeking sustainable solutions to the … feedstock shortage.”

Brother-and-sister team Moji and Tara Karimi founded Cemvita in 2017.

Investors in Cemvita include Oxy Low Carbon Ventures, an investment arm of Houston-based Occidental Petroleum, as well as BHP Group, Mitsubishi, and United Airlines Ventures.

Oxy Low Carbon Ventures and United Airlines Ventures are financing Cemvita’s work on sustainable jet fuel. United Airlines operates a hub at George Bush Intercontinental Airport Houston.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

University of Houston med school secures full accreditation

med school milestone

The University of Houston’s Tilman J. Fertitta Family College of Medicine has officially earned full accreditation after launching six years ago.

The designation comes from the Liaison Committee on Medical Education, which granted UH the maximum five-year review period available to a new medical school. To achieve the status, the committee reviewed the Fertitta College of Medicine's facilities, faculty and student outcomes, and curriculum to ensure the college met the highest standards in medical education.

“Full accreditation is not the finish line — it’s the foundation for everything we hope to accomplish in the years ahead,” Dr. Jonathan McCullers, vice president for health affairs at UH and dean of the Fertitta College of Medicine, said in a news release. “It strengthens our ability to attract outstanding students and faculty, expand our partnerships and prepare the next generation of physicians.”

Fertitta College of Medicine has graduated three classes of physicians, and every graduate from its most recent class secured a residency position. Enrollment has expanded from 30 students in its inaugural class to 65 students in its current class.

According to UH, about 70 percent of graduates have chosen to remain in Texas for further training, which is key to addressing the estimated 10,000 doctors needed to meet growing needs.

Fertitta College of Medicine opened for its first students in 2020, and now joins 14 other Texas schools as a fully LCME-accredited medical school. It also joins UTHealth Houston's McGovern Medical School and Baylor College of Medicine as one of three Houston-based LCME-accredited campuses.

The news comes after UH launched its health enterprise initiative, UH Health, in July and broke ground on its $77.5 million Medical Research Building next to the Fertitta College of Medicine last month.

“Building a medical school from the ground up is an extraordinary undertaking, and this milestone reflects the dedication of everyone who helped make it happen,” Dr. Stephen Scott, vice dean for education at the Fertitta College of Medicine, added in the release. “From developing an innovative curriculum to establishing the systems and partnerships that support our students, this has been a true team effort.”

Woodlands startup Mavria raises $130M to mass-produce AI data centers

seed funding

The Woodlands-based Mavria, which mass-produces factory-built modular AI data centers, just emerged from stealth mode with $130 million in funding at a $1 billion valuation.

Mavria raised the money in pre-seed and seed rounds led by Paradigm, an investment firm that concentrates on early-stage startups developing “pioneer” technology. Participants in the funding rounds include AMP PBC, Critical Frontier, Dream Ventures and Liquid 2 Ventures, co-founded by former NFL quarterback Joe Montana.

The company’s inaugural product, Terrain, is a prefabricated data center designed for AI labs, cloud computing providers and data center developers. Mavria says its platform avoids ground-up construction, delivering infrastructure more quickly and at a lower cost.

Mavria tells the Wall Street Journal that the first Terrain unit is being built at a Houston-area factory. The 5-megawatt Terrain system features power distribution, direct liquid cooling, controls and server racks.

“America sets the pace at the intelligence frontier. But the race is moving from the lab into the physical world,” Adam Blake, co-founder and CEO of Mavria, wrote in a blog post.

“Intelligence needs data centers. Data centers need power. Power needs factories, equipment, supply chains, and skilled workers, but much of that infrastructure is still built one custom project at a time, on timelines measured in years.”

Blake and Mavria’s two other co-founders, Nick Poradek and Seth Cohen, most recently worked at the U.S. Department of Energy. There, they focused on reforming the nuclear power sector.

From start to finish, it can take roughly three to six years to build a data center at an estimated cost of $10 million to $37 million per megawatt. Based on those figures, a 100-megawatt data center might cost as much as $3.7 billion.

Here are brief bios of Blake, Poradek and Cohen, who co-founded Mavria in May.

Adam Blake

Blake most recently was a senior advisor to U.S. Energy Secretary Chris Wright. He is co-founder and former CEO of Zego, a provider of energy management technology for property managers. Zego spun out from Brightergy, a commercial solar company. Blake is founder and former CEO of Brightergy.

Nick Poradek

Poradek, chief operating officer at Mavria, was also an advisor to the U.S. energy secretary. He is founder and former CEO of Spring-based Edera Energy, co-founder of The Woodlands-based craft-ice brand Clarity Ice, and founder and former CEO of The Woodlands-based Edera Capital. Poradek sold Edera Energy, a manufacturer of oilfield equipment, to Liberty Energy, a fracking company. Wright is Liberty’s founder and former chairman and CEO.

Seth Cohen

Cohen, chief strategy officer and chief legal officer at Mavria, was head of nuclear law and policy at the Department of Energy. He is also a former NASA advisor and a former attorney at Kirkland & Ellis.

“We believe in rapidly deploying infrastructure as a product, rather than custom-building every project,” Blake said. “We’re bringing together engineering, manufacturing, supply chains and capital so that every project makes us better at delivering the next.”